Gliosarcoma Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Astrocytoma, Grade IV
- +3 more
- Radiation
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022N
Recruiting
- Gliosarcoma
- +2 more
- Selinexor
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Glioblastoma
- +2 more
- TMZ
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
N
Recruiting
- Gliosarcoma
- MGMT-Unmethylated Glioblastoma
- Ipilimumab
- +6 more
- Birmingham, Alabama
- +283 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Gliosarcoma
- Supratentorial Glioblastoma
- Ipilimumab
- +3 more
- San Francisco, California
- +10 more
2022-04-05
Apr 5, 2022M
Recruiting
- Glioblastoma
- +2 more
- External Beam Radiation Therapy
- +5 more
- Rochester, MinnesotaMayo Clinic in Rochester
2022-04-04
Apr 4, 2022S
Active, not recruiting
- High Grade Glioma
- +6 more
- Encorafenib
- +3 more
- Birmingham, Alabama
- +5 more
2022-03-31
Mar 31, 2022N
Recruiting
- Glioblastoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
- Birmingham, Alabama
- +9 more
2022-03-30
Mar 30, 2022R
Active, not recruiting
- Glioblastoma
- Gliosarcoma
- Laboratory Biomarker Analysis
- +4 more
- Boston, Massachusetts
- +4 more
2022-03-21
Mar 21, 2022U
Active, not recruiting
- Glioblastoma Multiforme
- +2 more
- Birmingham, AlabamaUniversity of Alabama at Birmingham
2022-03-15
Mar 15, 2022F
Completed
- Glioblastoma
- Gliosarcoma
- 3-Dimensional Conformal Radiation Therapy
- +10 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-04
Mar 4, 2022M
Completed
- Cytomegalovirus Positive
- +5 more
- Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-03-01
Mar 1, 2022M
Recruiting
- Glioblastoma
- Gliosarcoma
- Nedisertib
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-02-08
Feb 8, 2022E
Active, not recruiting
- Glioblastoma
- Gliosarcoma
- Dose-Escalated Radiation Therapy
- +2 more
- Miami, Florida
- +2 more
2022-02-16
Feb 16, 2022L
Suspended
- Glioblastoma
- +4 more
- Plerixafor
- +3 more
- Palo Alto, CaliforniaStanford Cancer Institute Palo Alto
2022-02-01
Feb 1, 2022J
Active, not recruiting
- Giant Cell Glioblastoma
- +2 more
- bevacizumab
- +5 more
- Los Angeles, California
- +2 more
2022-02-10
Feb 10, 2022N
Active, not recruiting
- Glioblastoma
- Gliosarcoma
- Laboratory Biomarker Analysis
- +4 more
- Birmingham, Alabama
- +399 more
2022-02-09
Feb 9, 2022N
Active, not recruiting
- Anaplastic Astrocytoma
- +5 more
- Adavosertib
- +3 more
- Birmingham, Alabama
- +23 more
2022-01-28
Jan 28, 2022S
Active, not recruiting
- Glioblastoma
- +2 more
- Anti-LAG-3 Monoclonal Antibody BMS 986016
- +4 more
- Birmingham, Alabama
- +10 more
2022-01-28
Jan 28, 2022U
Recruiting
- Glioblastoma
- Gliosarcoma
- Mycophenolate Mofetil
- +3 more
- Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
2022-01-10
Jan 10, 2022N
Active, not recruiting
- Glioblastoma
- Gliosarcoma
- Laboratory Biomarker Analysis
- +3 more
- Birmingham, Alabama
- +9 more
2022-01-25
Jan 25, 2022N
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma
Recruiting
- Glioblastoma
- +5 more
- Sonication for opening of blood-brain barrier
- Chemotherapy, albumin-bound paclitaxel
- Chicago, IllinoisNorthwestern Memorial Hospital
2022-01-07
Jan 7, 2022A
Active, not recruiting
- Glioblastoma
- Gliosarcoma
- Temozolomide
- +3 more
- Phoenix, Arizona
- +211 more
2021-12-29
Dec 29, 2021N
Active, not recruiting
- Giant Cell Glioblastoma
- +5 more
- Bevacizumab
- +4 more
- Anchorage, Alaska
- +243 more
2021-12-21
Dec 21, 2021